Lisanti Capital Growth’s Procept Biorobotics PRCT Stock Holding History

Lisanti Capital Growth’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,890	Closed	-$1.13M	–	141
2025 Q4	$1.13M	Buy	+35,890	New	+$1.19M	0.27%	99
2025 Q3	–	Sell	-43,965	Closed	-$2.53M	–	132
2025 Q2	$2.53M	Buy	+43,965	New	+$2.49M	0.7%	63
2025 Q1	–	Sell	-40,685	Closed	-$3.28M	–	147
2024 Q4	$3.28M	Sell	40,685 -20,280	-33%	-$1.73M	0.79%	60
2024 Q3	$4.88M	Sell	60,965 -38,275	-39%	-$2.72M	1.24%	28
2024 Q2	$6.06M	Sell	99,240 -1,415	-1%	-$84.2K	1.46%	19
2024 Q1	$4.97M	Sell	100,655 -21,035	-17%	-$1M	1.21%	29
2023 Q4	$5.1M	Buy	+121,690	New	+$4.14M	1.2%	27
2023 Q3	–	Sell	-61,730	Closed	-$2.18M	–	163
2023 Q2	$2.18M	Buy	+61,730	New	+$2.04M	0.3%	107

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lisanti Capital Growth's PRCT Position: Q1 2026 in Review

Lisanti Capital Growth sold out of Procept Biorobotics (PRCT) in Q1 2026, closing a stake of 35,890 shares — an estimated $1.13M sold.

Lisanti Capital Growth first reported a position in PRCT in Q2 2023 and held it in 8 quarters. The position peaked at $6.06M in Q2 2024. 257 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

Lisanti Capital Growth reported no remaining Procept Biorobotics position as of Q1 2026 after selling out during the quarter.
Lisanti Capital Growth sold 35,890 Procept Biorobotics shares in Q1 2026, an estimated $1.13M.
Lisanti Capital Growth first reported a position in Procept Biorobotics in Q2 2023 and held it in 8 quarters.
Lisanti Capital Growth's Procept Biorobotics position peaked at $6.06M in Q2 2024.
257 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Lisanti Capital Growth's 13F filing for Q1 2026, filed 7 May 2026.